From Etiology to Targets: Molecular Vulnerabilities and Precision Therapy in Nasopharyngeal Carcinoma Driven by Risk Factors

Nasopharyngeal carcinoma (NPC) is the only malignancy etiologically linked to Epstein-Barr virus (EBV), with a high prevalence in specific geographic regions and ethnic populations. The host genetic predisposition, viral oncogenesis and environmental factors interact in a complex manner, collectively contributing to disease pathogenesis and forming a multifactorial etiological network. Accumulating evidence supports a triangle model, where these factors not only initiate and promote tumor progression, but also maintain long-term biological vulnerability, rendering the tumor responsive to various therapeutic interventions. EBV-encoded proteins, including Epstein-Barr nuclear antigen 1 (EBNA1), latent membrane protein 1 (LMP1) and latent membrane protein 2A (LMP2A), promote malignant transformation by stimulating oncogenic signaling pathways, enhancing immune evasion and modifying the tumor microenvironment. Host determinants, such as polymorphism of human leukocyte antigens (HLA), extracellular vesicle-mediated communication, and apolipoprotein B mRNA editing catalytic polypeptide-like 3 (APOBEC3), further modulate disease susceptibility. Environmental factors, including dietary toxins and chronic inflammatory stimulation, exacerbate all these pathogenic processes. Viral, genetic and microenvironmental signals are integrated into sustained survival and metastasis programs through persistent activation of key signaling pathways, notably nuclear factor kappa B (NF-κB) and phosphatidylinositol 3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K/AKT/mTOR). Also, metabolic reprogramming, epigenetic modification, and immunological inhibition contribute to a dynamic vulnerability network that links disease etiology to treatment options. Based on this model, recent studies have shifted toward a precision medicine paradigm that prioritizes molecular stratification over traditional anatomical staging, grounded in the mechanistic interplay between therapeutic sensitivity and oncogenic drivers, thereby enabling personalized treatment strategies.